BioSig Launches Enhanced Signal Processing Capabilities for Advanced Cardiac Signal Analysis Through its Electrophysiology Pl...
April 14 2021 - 9:29AM
The latest release represents the most advanced software
version of the PURE EPTM System, signal processing technology for
treatments of irregular heartbeats
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced the release of the PURE EP™ Software
Version 4. The latest release builds on the main system
capabilities of the PURE EPTM while improving the overall user
experience. The software upgrade will be rolled out to all new and
existing customers.
The latest software represents the most advanced software
version of the PURE EPTM System. The update adds valuable tools to
shorten system set up time and bring innovative features for faster
real-time signal analysis, potentially improving the efficiency and
accuracy of EP procedures.
Advances in the new PURE EPTM Software Version 4 include user
interface enhancements for a more compelling assessment of
arrhythmia morphologies, clinical template management for an
efficient case setup process, and other software functionalities
for real-time signal visualization, such as the “Differential
Analysis” allowing the simultaneous display of a channel using
various filter settings to assess specific characteristics of a
signal or the enhanced “Digital Zoom” permitting to instantly focus
on important physiologic details while preserving a high
signal-to-noise ratio.
“The launch of the PURE EPTM Software Version 4 is the result of
a collaborative effort between our engineering team and our
physician customers to identify the most critical needs and
translate those into innovative advancements. Our comprehensive
product portfolio consists of a series of commercial software
upgrades and novel software modules, and we are dedicated to
driving the innovation as we accelerate commercial sales this
year,” commented Olivier Chaudoir, Sr. Director of Marketing,
BioSig Technologies, Inc.
More than 660 patient cases have been conducted using the PURE
EPTM System by 40 physicians in eight clinical sites to date.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EPTM System is
a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking
statements.” Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward- looking statements are not
guarantees of future performance, are based on certain assumptions
and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company’s control, and
cannot be predicted or quantified and consequently, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
without limitation, risks and uncertainties associated with (i) the
geographic, social and economic impact of COVID-19 on our ability
to conduct our business and raise capital in the future when
needed, (ii) our inability to manufacture our products and product
candidates on a commercial scale on our own, or in collaboration
with third parties; (iii) difficulties in obtaining financing on
commercially reasonable terms; (iv) changes in the size and nature
of our competition; (v) loss of one or more key executives or
scientists; and (vi) difficulties in securing regulatory approval
to market our products and product candidates. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are
urged to read these documents free of charge on the SEC’s website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024